1
|
Lescarbotte F, Romano G, Balleyguier C, Arfi Rouche J, Ilenko A, Leymarie N. [Extensive transfixing skin necrosis after breast biopsy under local anesthesia: About four cases]. ANN CHIR PLAST ESTH 2024; 69:27-33. [PMID: 37121845 DOI: 10.1016/j.anplas.2023.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 04/03/2023] [Accepted: 04/13/2023] [Indexed: 05/02/2023]
Abstract
INTRODUCTION Local anesthetics with adrenaline are widely used in routine practice and have long proven their benefits and safety. The rare complications due to their use mainly concern immuno-allergic and vascular mechanisms. DESCRIPTION In this article, we present four similar cases of early transfixing skin necrosis occurring after radioguided breast biopsy under local anesthesia using epinephrine local anesthetics in the context of a diagnostic approach to breast cancer. DISCUSSION Although the literature is comforting about the use of local anesthetics, even on the extremities, severe skin complications continue to be reported sporadically. The analysis and understanding of these phenomena would allow, in the long run, to avoid them and to reduce their importance. CONCLUSION The occurrence of skin necrosis after breast biopsy under radiographic control is rare and seems to be related to the local anesthetic procedure. Although similar cases have been reported in the literature, it does not seem possible today to conclude on the exact physiopathology of these complications. A better knowledge of the pathophysiology of these complications would help to avoid their occurrence in the future.
Collapse
Affiliation(s)
- Francois Lescarbotte
- Department of Plastic and Breast Surgery, Gustave-Roussy Cancer Campus, Grand Paris, France.
| | - Golda Romano
- Department of Plastic and Breast Surgery, Gustave-Roussy Cancer Campus, Grand Paris, France
| | - Corinne Balleyguier
- Department of Medical Imagery, Gustave-Roussy Cancer Campus, Grand Paris, France
| | - Julia Arfi Rouche
- Department of Medical Imagery, Gustave-Roussy Cancer Campus, Grand Paris, France
| | - Anna Ilenko
- Department of Plastic and Breast Surgery, Gustave-Roussy Cancer Campus, Grand Paris, France
| | - Nicolas Leymarie
- Department of Plastic and Breast Surgery, Gustave-Roussy Cancer Campus, Grand Paris, France
| |
Collapse
|
2
|
Younsi M, Rives JP, Ilenko A, Demiri M. Dexmedetomidine effect on opioid consumption in breast reconstruction surgery. J Plast Reconstr Aesthet Surg 2023; 85:155-158. [PMID: 37494849 DOI: 10.1016/j.bjps.2023.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2023] [Revised: 05/26/2023] [Accepted: 07/04/2023] [Indexed: 07/28/2023]
Affiliation(s)
- Malek Younsi
- Department of Anesthesia, Gustave Roussy Cancer Center, Villejuif, France
| | | | - Anna Ilenko
- Department of Oncologic and Reconstructive Surgery, Gustave Roussy Cancer Center, Villejuif, France
| | - Migena Demiri
- Department of Anesthesia, Gustave Roussy Cancer Center, Villejuif, France.
| |
Collapse
|
3
|
Eymerit-Morin C, Ilenko A, Gaillard T, Varinot J, Compérat E, Bendifallah S, Darai E. PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases. Eur J Histochem 2021; 65. [PMID: 33728864 PMCID: PMC7967270 DOI: 10.4081/ejh.2021.3185] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Accepted: 02/10/2021] [Indexed: 12/13/2022] Open
Abstract
Therapeutic strategies for epithelial ovarian cancers are evolving with the advent of immunotherapy, such as PD-L1 inhibitors, with encouraging results. However, little data are available on PDL-1 expression in ovarian cancers. Thus, we set out to determine the PD-L1 expression according to histological subtype. We evaluated the expression of two PD-L1 clones – QR1 and E1L3N – with two scores, one based on the percentage of labeled tumor cells (tumor proportion score, TPS) and the other on labeled immune cells (combined proportion score, CPS) in a consecutive retrospective series of 232 ovarian cancers. PD-L1 expression was more frequent in high grade serous carcinoma (27.5% with E1L3N clone and 41.5% with QR1 clone), grade 3 endometrioid carcinoma (25% with E1L3N clone and 50% with QR1 clone), and clear-cell carcinomas (27.3% with E1L3N clone and 29.6% with QR1 clone) than other histological subtypes with CPS score. Using the CPS score, 17% of cases were labeled with E1L3N vs 28% with QR1. Using the TPS score, 14% of cases were positive to E1L3N vs 17% for QR1. For TPS and CPS, respectively, 77% and 78% of the QR1 cases were concordant with E1L3N for the thresholds of 1%. Overall and progression-free survival between PD-L1 positive and PD-L1 negative patients were not different across all histological types, and each subtype in particular for serous carcinomas expressing PD-L1. Expression of PD-L1 is relatively uncommon in epithelium ovarian tumors. When positive, usually <10% of tumor cells are labeled. QR1 clone and CPS appear the best tools to evaluate PD-L1 expression.
Collapse
Affiliation(s)
- Caroline Eymerit-Morin
- Department of Anatomopathology, Tenon University Hospital, Assistance publique des Hopitaux de Paris (APHP.6), Sorbonne Université, Paris.
| | - Anna Ilenko
- Gynecologic and Obstetrics Department, Tenon University Hospital, Assistance publique des Hôpitaux de Paris (APHP.6), Sorbonne Université, Paris.
| | - Thomas Gaillard
- Gynecologic and Obstetrics Department, Tenon University Hospital, Assistance publique des Hôpitaux de Paris (APHP.6), Sorbonne Université, Paris, France.
| | - Justine Varinot
- Department of Anatomopathology, Tenon University Hospital, Assistance publique des Hopitaux de Paris (APHP.6), Sorbonne Université, Paris.
| | - Eva Compérat
- Department of Anatomopathology, Tenon University Hospital, Assistance publique des Hopitaux de Paris (APHP.6), Sorbonne Université, Paris.
| | - Sofiane Bendifallah
- Gynecologic and Obstetrics Department, Tenon University Hospital, Assistance publique des Hôpitaux de Paris (APHP.6), Sorbonne Université, Paris.
| | - Emile Darai
- Gynecologic and Obstetrics Department, Tenon University Hospital, Assistance publique des Hôpitaux de Paris (APHP.6), Sorbonne Université, Paris.
| |
Collapse
|
4
|
Gouy S, Seebacher V, Chargari C, Terroir M, Grimaldi S, Ilenko A, Maulard A, Genestie C, Leary A, Pautier P, Morice P, Deandreis D. False negative rate at 18F-FDG PET/CT in para-aortic lymphnode involvement in patients with locally advanced cervical cancer: impact of PET technology. BMC Cancer 2021; 21:135. [PMID: 33549033 PMCID: PMC7866875 DOI: 10.1186/s12885-021-07821-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Accepted: 01/19/2021] [Indexed: 11/25/2022] Open
Abstract
Background The identification of factors responsible for false negative (FN) rate at 18F- Fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in para-aortic (PA) lymph nodes in the presurgical staging of patients with locally advanced cervical cancer (LACC) is challenging. The aim of this study was to evaluate the impact of PET/CT technology. Methods A total of 240 consecutive patients with LACC (International Federation of Gynecology and Obstetrics, FIGO, stage IB2-IVA) and negative Magnetic Resonance Imaging (MRI) and/or Computed Tomography (CT) and negative 18F-FDG PET/CT in the PA region, undergoing laparoscopic PA lymphadenectomy before chemoradiotherapy were included. The FN rate in patients studied with Time of flight (TOF) PET/CT (TOF PET) or non-Time of flight PET/CT (no-TOF PET) technology was retrospectively compared. Results Patients presented with FIGO stage IB (n = 78), stage IIA-B (n = 134), stage III (n = 18) and stage IVa (n = 10), squamous cell carcinoma (n = 191) and adenocarcinoma (n = 49). 141/240 patients were evaluated with no-TOF PET/CT and 99/240 with TOF PET/CT. Twenty-two patients (9%) had PA nodal involvement at histological analysis and considered PET/CT FN findings. The FN rate was 8.5% for no-TOF PET and 10% for TOF PET subgroup respectively (p = 0.98). Ninety patients (38%) presented with pelvic node uptakes at PET/CT. The FN rate in the PA region was 18% (16/90) and 4% (6/150) in patients with and without pelvic node involvement at PET/CT respectively (19 vs 3% for no-TOF PET and 17 vs 5% for TOF PET subgroup). Conclusions In LACC, FN rate in PA lymph nodes detection is a clinical issue even for modern PET/CT, especially in patients with pelvic uptake. Surgical lymphadenectomy should be performed in case of negative PET/CT at PA level in these patients, while it could be discussed in the absence of pelvic uptake.
Collapse
Affiliation(s)
- Sebastien Gouy
- Department of Gynecologic Surgery, Gustave Roussy and Paris Saclay, 114 Rue Edouard Vaillant, Villejuif, France.,University Paris Sud, Orsay, France.,Unit INSERM 1030, 114 Rue Edouard Vaillant, Villejuif, France
| | - Veronika Seebacher
- Department of Gynecologic Surgery, Gustave Roussy and Paris Saclay, 114 Rue Edouard Vaillant, Villejuif, France
| | - Cyrus Chargari
- University Paris Sud, Orsay, France.,Department of Radiotherapy and Brachytherapy Unit, Gustave Roussy and Paris Saclay, 114 Rue Edouard Vaillant, Villejuif, France.,Effets biologiques des rayonnements, Institut de Recherche Biomédicale des Armées, Bretigny-sur-Orge, France
| | - Marie Terroir
- Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Paris Saclay, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - Serena Grimaldi
- Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Paris Saclay, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - Anna Ilenko
- Department of Gynecologic Surgery, Gustave Roussy and Paris Saclay, 114 Rue Edouard Vaillant, Villejuif, France
| | - Amandine Maulard
- Department of Gynecologic Surgery, Gustave Roussy and Paris Saclay, 114 Rue Edouard Vaillant, Villejuif, France
| | - Catherine Genestie
- Department of Pathology, Gustave Roussy and Paris Saclay, 114 Rue Edouard Vaillant, Villejuif, France
| | - Alexandra Leary
- Department of Medical Oncology, Gustave Roussy and Paris Saclay, 114 Rue Edouard Vaillant, Villejuif, France
| | - Patricia Pautier
- Department of Medical Oncology, Gustave Roussy and Paris Saclay, 114 Rue Edouard Vaillant, Villejuif, France
| | - Philippe Morice
- Department of Gynecologic Surgery, Gustave Roussy and Paris Saclay, 114 Rue Edouard Vaillant, Villejuif, France.,University Paris Sud, Orsay, France.,Unit INSERM 1030, 114 Rue Edouard Vaillant, Villejuif, France
| | - Désirée Deandreis
- Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Paris Saclay, 114 Rue Edouard Vaillant, 94800, Villejuif, France. .,Department of Medical Sciences, Nuclear Medicine Division, the University of Turin, C.so Dogliotti, 14 10126, Turin, Italy.
| |
Collapse
|
5
|
Larouzee E, Allegre L, Boudy AS, Ilenko A, Selleret L, Zilberman S, Owen C, Gligorov J, Richard S, Thomassin-Naggara I, Chabbert-Buffet N, Darai E, Bendifallah S. Predicting the likelihood of recurrence of pregnancy-associated breast cancer: Nomogram based on analysis of the French cancer network: Cancer Associé à La Grossesse. J Gynecol Obstet Hum Reprod 2020; 50:101766. [PMID: 32325267 DOI: 10.1016/j.jogoh.2020.101766] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2020] [Revised: 04/10/2020] [Accepted: 04/14/2020] [Indexed: 12/18/2022]
Abstract
OBJECTIVE Pregnancy associated breast cancer (PABC) are defined as breast cancer diagnosed during pregnancy and during the year following delivery. The prediction of poor prognosis events (PPE) such as recurrence is a major medical challenge of management for women with PABC. The aim of this study was to build a nomogram based on selected clinical and histological variables to predict recurrence. STUDY DESIGN This retrospective study included 96 patients with PABC from January 2002 to January 2018. A multivariate Cox analysis of selected risk factors was performed and a nomogram to predict recurrence was built. The nomogram was internally validated. RESULTS The overall recurrence rate was 22% (21/95) and the 3-years recurrence rate was 13% (12/95). Age at diagnosis, histological type, immuno-histological class, tumor stage (TNM), node stage (TNM) were associated with PPE in univariate analysis, and were included in the final Cox model to develop the nomogram. The predictive model had a concordance index of 0.83 (95% Confidence Interval (CI), 0.81-0.85) and 0.78 (95% CI, 0.76-0.80) before and after the 200 repetitions of bootstrap sample corrections, respectively, and showed a good calibration. CONCLUSION Our results support the use of the present nomogram based on 5 clinical and pathological characteristics to predict PPE in PABC with a high concordance. External validation is required to recommend this nomogram in routine practice.
Collapse
Affiliation(s)
- Elise Larouzee
- Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France.
| | - Lucie Allegre
- Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France
| | - Anne-Sophie Boudy
- Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France; Centre CALG (Cancer Associé à La Grossesse), France
| | - Anna Ilenko
- Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France; Centre CALG (Cancer Associé à La Grossesse), France
| | - Lise Selleret
- Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France; Centre CALG (Cancer Associé à La Grossesse), France
| | - Sonia Zilberman
- Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France; Centre CALG (Cancer Associé à La Grossesse), France
| | - Clémentine Owen
- Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France; Centre CALG (Cancer Associé à La Grossesse), France
| | - Joseph Gligorov
- Centre CALG (Cancer Associé à La Grossesse), France; Department of Oncology, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France
| | - Sandrine Richard
- Centre CALG (Cancer Associé à La Grossesse), France; Department of Oncology, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France
| | - Isabelle Thomassin-Naggara
- Department of Radiology, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France
| | - Nathalie Chabbert-Buffet
- Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France; Centre CALG (Cancer Associé à La Grossesse), France; UMRS-938 Sorbonne University, Paris, France
| | - Emile Darai
- Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France; Centre CALG (Cancer Associé à La Grossesse), France; UMRS-938 Sorbonne University, Paris, France
| | - Sofiane Bendifallah
- Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Faculté de Médecine Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France; Centre CALG (Cancer Associé à La Grossesse), France; UMRS-938 Sorbonne University, Paris, France
| |
Collapse
|
6
|
Owen C, Bendifallah S, Jayot A, Ilenko A, Arfi A, Boudy AS, Richard S, Varinot J, Thomassin-Naggara I, Bazot M, Daraï É. [Lymph node management in endometrial cancer]. Bull Cancer 2019; 107:686-695. [PMID: 31648773 DOI: 10.1016/j.bulcan.2019.06.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Accepted: 06/16/2019] [Indexed: 01/03/2023]
Abstract
In 2018, around 382,100 new cases of endometrial cancer (EC) were reported worldwide, accounting for about 4.4% of all new cases of cancer in women. In France, in 2018, the EC is the first gynecological cancer in incidence and the fourth cancer in women. The rationale for the therapeutic management of EC is based on the estimation of a theoretical risk of recurrence and lymph node metastasis using MRI and preoperative biopsy criteria. However, lymph node status remains the determining factor of adjuvant treatment. In order to reduce the morbidity of lymphadenectomy, the concept of sentinel lymph node biopsy (SLN) has been developed. The SLN technique has evolved in recent years, thanks to the advent of robotics and the creation of fluorescence detection cameras. It has been shown that detection of SLN with Indocyanine Green (ICG) allows for more frequent bilateral migration of 88 to 100% and better detection of pelvic GS in 97% of cases with a decrease in morbidity. Recently, in view of the absence of a therapeutic role of lymph node staging, the operational risks and the delay of adjuvant treatments, in case of pelvic lymph node metastasis on definitive histological examination, the question of secondarily performing paraaortic lymphadenectomy arises. The SLN procedure, extended to all early-stage endometrial cancers, should lead to a major reduction in the use of secondary staging and better adaptation of adjuvant therapy.
Collapse
Affiliation(s)
- Clémentine Owen
- AP-HP, université Sorbonne, hôpital Tenon, service de gynécologie obstétrique et médecine de la reproduction humaine, 4, rue de La Chine, 75020 Paris, France.
| | - Sofiane Bendifallah
- AP-HP, université Sorbonne, hôpital Tenon, service de gynécologie obstétrique et médecine de la reproduction humaine, 4, rue de La Chine, 75020 Paris, France; Université Sorbonne, GRC 6 -UPMC : Centre expert en endométriose (C3E), 75005 Paris, France; Faculté de Médecine Sorbonne Université, Site Saint-Antoine, 27, rue Chaligny, 75571 Paris cedex 12, France
| | - Aude Jayot
- AP-HP, université Sorbonne, hôpital Tenon, service de gynécologie obstétrique et médecine de la reproduction humaine, 4, rue de La Chine, 75020 Paris, France
| | - Anna Ilenko
- AP-HP, université Sorbonne, hôpital Tenon, service de gynécologie obstétrique et médecine de la reproduction humaine, 4, rue de La Chine, 75020 Paris, France
| | - Alexandra Arfi
- AP-HP, université Sorbonne, hôpital Tenon, service de gynécologie obstétrique et médecine de la reproduction humaine, 4, rue de La Chine, 75020 Paris, France
| | - Anne Sophie Boudy
- AP-HP, université Sorbonne, hôpital Tenon, service de gynécologie obstétrique et médecine de la reproduction humaine, 4, rue de La Chine, 75020 Paris, France
| | - Sandrine Richard
- AP-HP, université Sorbonne, Alliance pour la recherche en cancérologie (APREC), service d'oncologie médicale, hôpital Tenon, 4, rue de la Chine, 75020 Paris, France
| | - Justine Varinot
- AP-HP, université Sorbonne, service d'anatomopathologie, hôpital Tenon, 4, rue de la Chine, 75020 Paris, France
| | - Isabelle Thomassin-Naggara
- AP-HP, université Sorbonne, service d'anatomopathologie, hôpital Tenon, 4, rue de la Chine, 75020 Paris, France
| | - Marc Bazot
- AP-HP, université Sorbonne, UPMC université Paris 6, institut universitaire de cancérologie, hôpital Tenon, service d'imagerie, 4, rue de la Chine, 75020 Paris, France
| | - Émile Daraï
- AP-HP, université Sorbonne, hôpital Tenon, service de gynécologie obstétrique et médecine de la reproduction humaine, 4, rue de La Chine, 75020 Paris, France; Université Sorbonne, GRC 6 -UPMC : Centre expert en endométriose (C3E), 75005 Paris, France; Faculté de Médecine Sorbonne Université, Site Saint-Antoine, 27, rue Chaligny, 75571 Paris cedex 12, France
| |
Collapse
|
7
|
Favier A, Owen C, Jayot A, Ilenko A, Daraï E, Bendifallah S. [How I do…to perfom a laparoscopic colorectal discoid resection for endometriosis]. ACTA ACUST UNITED AC 2019; 47:698-699. [PMID: 31352144 DOI: 10.1016/j.gofs.2019.07.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2019] [Indexed: 11/17/2022]
Affiliation(s)
- A Favier
- Service de chirurgie gynécologique, hôpital Tenon, 4, rue de la Chine, 75012 Paris, France.
| | - C Owen
- Service de chirurgie gynécologique, hôpital Tenon, 4, rue de la Chine, 75012 Paris, France
| | - A Jayot
- Service de chirurgie gynécologique, hôpital Tenon, 4, rue de la Chine, 75012 Paris, France
| | - A Ilenko
- Service de chirurgie gynécologique, hôpital Tenon, 4, rue de la Chine, 75012 Paris, France
| | - E Daraï
- Service de chirurgie gynécologique, hôpital Tenon, 4, rue de la Chine, 75012 Paris, France
| | - S Bendifallah
- Service de chirurgie gynécologique, hôpital Tenon, 4, rue de la Chine, 75012 Paris, France
| |
Collapse
|
8
|
Bendifallah S, Ilenko A, Daraï E. High risk endometrial cancer: Clues towards a revision of the therapeutic paradigm. J Gynecol Obstet Hum Reprod 2019; 48:863-871. [PMID: 31176047 DOI: 10.1016/j.jogoh.2019.06.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Revised: 05/16/2019] [Accepted: 06/04/2019] [Indexed: 11/18/2022]
Abstract
INTRODUCTION Endometrial cancer (EC) is a major cause of mortality worldwide with nearly 200 000 cases diagnosed annually. The recent ESMO-ESGO-ESTRO guidelines include a new classification defining a heterogeneous high-risk group of recurrence (HR) comprising: (i) endometrioid (type 1) FIGO stage IB grade 3 tumors (type 1/G3ECs), (ii) non-endometrioid tumors (type 2) and (iii) advanced stages whatever the histological type (Colombo et al., 2016). AREAS COVERED The aim of this review is to summarize current evidence for therapeutic approaches in HR-EC according to the updated ESMO-ESGO-ESTRO classification by discussing the following issues: i) HR-EC heterogeneity, (ii) prognostic factors and current classification, and (iii) optimal staging strategies (site and extent) and the role of adjuvant treatment. EXPERT COMMENTARY HR-EC treatment is based on surgery, radiation therapy, brachytherapy, and chemotherapy, either alone or sequentially, in combination with other treatments depending on disease stage, histological grade and risk group. Specific trials are needed to establish the role of systematic pelvic and paraaortic lymphadenectomy, adjuvant therapies and targeted drugs. Although molecular characterization has been reported to customize therapeutic strategies and thereby improve therapeutic outcomes in EC, none of the targeted agents investigated (antiangiogenic and mTOR/PI3K pathway inhibitor agents) have resulted in a change in clinical practice in HR-EC.
Collapse
Affiliation(s)
- S Bendifallah
- Department of Obstetrics and Gynaecology, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France; INSERM UMR S 938, Sorbonne université, Paris 6, France
| | - A Ilenko
- Department of Obstetrics and Gynaecology, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France.
| | - E Daraï
- Department of Obstetrics and Gynaecology, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Sorbonne Université, Institut Universitaire de Cancérologie (IUC), France; INSERM UMR S 938, Sorbonne université, Paris 6, France
| |
Collapse
|
9
|
Allègre L, Arfi A, Larouzée E, Ilenko A, Bendifallah S, Darai E, Stroumza N, Zilberman S. [How I do…an oncoplastic surgery by T inverted mammoplasty with superior pedicle?]. ACTA ACUST UNITED AC 2018; 47:85-87. [PMID: 30503237 DOI: 10.1016/j.gofs.2018.10.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Indexed: 11/19/2022]
Affiliation(s)
- L Allègre
- Département de gynécologie et obstétrique, hôpital Tenon, hôpitaux de Paris, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France.
| | - A Arfi
- Département de gynécologie et obstétrique, hôpital Tenon, hôpitaux de Paris, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - E Larouzée
- Département de gynécologie et obstétrique, hôpital Tenon, hôpitaux de Paris, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - A Ilenko
- Département de gynécologie et obstétrique, hôpital Tenon, hôpitaux de Paris, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France
| | - S Bendifallah
- Département de gynécologie et obstétrique, hôpital Tenon, hôpitaux de Paris, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France; Inserm UMR_S_707, « Epidémiologie, Information des Systèmes, Modèles », Sorbonne université, 75006 Paris6, France; Groupe de Recherche Clinique 6 (GRC6-UPMC) : Centre expert en endométriose (C3E), hôpital tenon, 4 rue de la Chine, 75020 Paris 20, France; UMR_S938 Sorbonne université, 184 rue du Faubourg-Saint-Antoine, 75006 Paris 6, France
| | - E Darai
- Département de gynécologie et obstétrique, hôpital Tenon, hôpitaux de Paris, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France; Inserm UMR_S_707, « Epidémiologie, Information des Systèmes, Modèles », Sorbonne université, 75006 Paris6, France; Groupe de Recherche Clinique 6 (GRC6-UPMC) : Centre expert en endométriose (C3E), hôpital tenon, 4 rue de la Chine, 75020 Paris 20, France; UMR_S938 Sorbonne université, 184 rue du Faubourg-Saint-Antoine, 75006 Paris 6, France
| | - N Stroumza
- Département de chirurgie plastique et reconstructrice, hôpital Tenon, assistance publique des hôpitaux de Paris (AP-HP), Sorbonne université, 4 rue de la Chine, 75020 Paris, France
| | - S Zilberman
- Département de gynécologie et obstétrique, hôpital Tenon, hôpitaux de Paris, Sorbonne université, AP-HP, 4, rue de la Chine, 75020 Paris, France
| |
Collapse
|
10
|
Benoit L, Arfi A, Quilichini O, Ilenko A, Bendifallah S, Darai E, Zilberman S. [How do I do … a lumpectomy with an external oncoplasty]. ACTA ACUST UNITED AC 2018; 46:740-743. [PMID: 30243942 DOI: 10.1016/j.gofs.2018.08.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Indexed: 11/16/2022]
Affiliation(s)
- L Benoit
- Département de gynécologie and obstétrique, université Paris Sorbonne, hôpital Tenon, Assistance publique des Hôpitaux de Paris (AP-HP), 4, rue de la Chine, 75020 Paris, France.
| | - A Arfi
- Département de gynécologie and obstétrique, université Paris Sorbonne, hôpital Tenon, Assistance publique des Hôpitaux de Paris (AP-HP), 4, rue de la Chine, 75020 Paris, France
| | - O Quilichini
- Département de gynécologie and obstétrique, université Paris Sorbonne, hôpital Tenon, Assistance publique des Hôpitaux de Paris (AP-HP), 4, rue de la Chine, 75020 Paris, France
| | - A Ilenko
- Département de gynécologie and obstétrique, université Paris Sorbonne, hôpital Tenon, Assistance publique des Hôpitaux de Paris (AP-HP), 4, rue de la Chine, 75020 Paris, France
| | - S Bendifallah
- Département de gynécologie and obstétrique, université Paris Sorbonne, hôpital Tenon, Assistance publique des Hôpitaux de Paris (AP-HP), 4, rue de la Chine, 75020 Paris, France; Inserm UMR_S_707, « épidémiologie, information des systèmes, Modeling », université Paris Sorbonne, Paris, France; Groupe de recherche clinique 6 (GRC6-UPMC), centre expert en endométriose (C3E), Paris, France; UMR_S938, université Paris Sorbonne, Paris, France
| | - E Darai
- Département de gynécologie and obstétrique, université Paris Sorbonne, hôpital Tenon, Assistance publique des Hôpitaux de Paris (AP-HP), 4, rue de la Chine, 75020 Paris, France; Inserm UMR_S_707, « épidémiologie, information des systèmes, Modeling », université Paris Sorbonne, Paris, France; Groupe de recherche clinique 6 (GRC6-UPMC), centre expert en endométriose (C3E), Paris, France; UMR_S938, université Paris Sorbonne, Paris, France
| | - S Zilberman
- Département de gynécologie and obstétrique, université Paris Sorbonne, hôpital Tenon, Assistance publique des Hôpitaux de Paris (AP-HP), 4, rue de la Chine, 75020 Paris, France
| |
Collapse
|
11
|
Ilenko A, Sergent F, Mercuzot A, Zitoun M, Chauffert B, Foulon A, Gondry J, Chevreau J. Could Patients Older than 75 Years Benefit from a Systematic Breast Cancer Screening Program? Anticancer Res 2017; 37:903-907. [PMID: 28179350 DOI: 10.21873/anticanres.11397] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2016] [Revised: 01/26/2017] [Accepted: 01/27/2017] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM To assess prognosis of women aged 75 and older according to breast cancer (BC) diagnosis circumstances. PATIENTS AND METHODS A retrospective cohort study was conducted in the Amiens, France, regional oncologic referral center between 2005 and 2015. Two groups were formed depending on whether the patients followed clinical manifestations (CM) or a prescribed systematic mammography (SM). RESULTS Three hundred and ninenty-three patients were selected. CM and SM represented 72% and 14.5% of BC diagnosis circumstances, respectively. In the SM group statistically significant differences included: earlier stage cancer diagnosis (tumor stages 0 and 1 accounted for 6.3% and 61.4% of cases, respectively), less lymph node invasions (35.7% and 8.8%) and metastases (19.1% and 0%), more frequent possibility of conservative surgery (25.6% and 74.5%), improved global and disease-free survival rates (by 14.2 and 18.4 months). CONCLUSION Screening seems to improve prognosis of older BC patients; this constitutes a strong argument for reconsidering age limits of national BC screening programs.
Collapse
Affiliation(s)
- Anna Ilenko
- Department of Gynecology, University Hospital of Amiens, Amiens, France
| | - Fabrice Sergent
- Department of Gynecology, University Hospital of Amiens, Amiens, France
| | - Antonin Mercuzot
- Department of Gynecology, University Hospital of Amiens, Amiens, France
| | - Mickaël Zitoun
- Department of Radiology, University Hospital of Amiens, Amiens, France
| | - Bruno Chauffert
- Department of Medical Oncology, University Hospital of Amiens, Amiens, France
| | - Arthur Foulon
- Department of Gynecology, University Hospital of Amiens, Amiens, France
| | - Jean Gondry
- Department of Gynecology, University Hospital of Amiens, Amiens, France
| | - Julien Chevreau
- Department of Gynecology, University Hospital of Amiens, Amiens, France
| |
Collapse
|
12
|
Affiliation(s)
- M Gosset
- Département de gynécologie obstétrique, centre hospitalier intercommunal André-Grégoire, 56, boulevard de la Boissière, 93100 Montreuil, France.
| | - A Ilenko
- Département de gynécologie obstétrique, centre hospitalier universitaire, Amiens-Picardie, Site Sud, 80054 Amiens, France
| | - J Bouyou
- Département de gynécologie obstétrique, centre hospitalier universitaire, Amiens-Picardie, Site Sud, 80054 Amiens, France
| | - B Renevier
- Département de gynécologie obstétrique, centre hospitalier intercommunal André-Grégoire, 56, boulevard de la Boissière, 93100 Montreuil, France
| |
Collapse
|